Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada

Lee Mozessohn, MD, Matthew Cheung, MD MS, FRCP, Nicole Mittmann, PhD, Craig C. Earle, MD, Ning Liu, Rena Buckstein, MD FRCPC

Blood (2018) 132 (Supplement 1): 834.

https://doi.org/10.1182/blood-2018-99-110223

Published: 2018

Journal Articles

Diagnosis to Treatment Interval in DLBCL Is Predictive of Overall Survival in a Large, Population-Based Registry

Danielle N. Blunt, BMBS, Liam Smyth, MD FRCPath, Evgenia Gatov, Chenthila Nagamuthu, MPH, Rena Buckstein, MD FRCPC, Ruth Croxford, MSc, Matthew Cheung, MD MS, FRCP

Blood (2018) 132 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2018-99-120313

Published: 2018

Journal Articles

Appropriateness of B12 Administration in a Real-World Population

William K Silverstein, MD, Yulia Lin, MD FRCPC, Christoffer Dharma, MSc, Ruth Croxford, MSc, Matthew Cheung, MD MS, FRCP

Blood (2018) 132 (Supplement 1): 2227.

https://doi.org/10.1182/blood-2018-99-110264

Published: 2018

Journal Articles

Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

Abi Vijenthira, MD, Kelvin Chan, MD PhD, Matthew Cheung, MD MS, FRCP, Anca Prica, MD

Blood (2018) 132 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2018-99-113103

Published: 2018

Journal Articles

Examining Convergent Construct Validity and Inter-Rater Reliability Between ESMO-MCBS and ASCO-VF When Evaluating Hematologic Malignancies

Matthew Cheung, MD MS, FRCP, Ihsan Albakri, Robert Mason, Ronak Saluja, Sierra Cheng, Vanessa Arciero, Louis Everest, Kelvin Chan, MD PhD

Blood (2018) 132 (Supplement 1): 4800.

https://doi.org/10.1182/blood-2018-99-119631

Published: 2018

Journal Articles

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Liam Smyth, MD FRCPath, Rena Buckstein, MD FRCPC, Pennell Nancy, BSc, Rashmi Weerasinghe, Matthew Cheung, MD MS, FRCP, Eugenia Piliotis, MD FRCP, MD, Kevin Imrie, MD, David Spaner, MD PhD, Marciano D. Reis, MD, Lisa Chodirker, MD, Zeina Ghorab, Violet ruth,nancy Milliken, Angela Boudreau, RN, BScN, MN, CON(C), Neil Berinstein, MD

Blood (2017) 130 (Supplement 1): 4069.

https://doi.org/10.1182/blood.V130.Suppl_1.4069.4069

Published: 2017

Journal Articles

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Anca Prica, MD FRCP(C), Annette E Hay, Michael Crump, MD, Nicole Mittman, Lois E. Shepherd, Ralph Meyer, MDFRCPC, Kevin Imrie, MD, Nancy A. Risebrough, Marina S Djurfeldt, MSc, Bingshu E. Chen, Matthew Cheung, MD MS, FRCP

Blood (2017) 130 (Supplement 1): 4673.

https://doi.org/10.1182/blood.V130.Suppl_1.4673.4673

Published: 2017

Journal Articles

Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent

James K R Stevenson, MD MSc, Lucy Qiao, MS, MPH, Kelvin Chan, MD PhD, Jaclyn Beca, MSc, Wanrundee Isaranuwatchai, PhD, Helen Guo, BS, Deborah Schwarz, PhD, Jessica Arias, BA, MACP, Scott Gavura, BSPharm, MBA, C. Tom Kouroukis, MDMSc,FRCPC, Matthew Cheung, MD MS, FRCP

Blood (2017) 130 (Supplement 1): 1557.

https://doi.org/10.1182/blood.V130.Suppl_1.1557.1557

Published: 2017

Journal Articles

Days Spent at Home in the Last 6 Months of Life. a Potential Patient-Determined Quality Indicator for Patients with Hematologic Malignancies at the End of Life

Matthew Cheung, MD MS, FRCP, Sarah Andersen, MD, Craig C. Earle, MDMSc, Ruth Croxford, Simron Singh, MD MS, FRCPC

Blood (2017) 130 (Supplement 1): 281.

https://doi.org/10.1182/blood.V130.Suppl_1.281.281

Published: 2017

Journal Articles

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Tony Reiman, MD, Kerry J. Savage, MD MSc, Michael Crump, MD, Matthew Cheung, MD, David A. MacDonald, MD, Rena Buckstein, MD, Stephen Couban, MD, Eugenia Piliotis, MD, Kevin R Imrie, MD, David Spaner, MD PhD, Sudeep Shivakumar, MD, John Kuruvilla, MD, Diego Villa, Lois E. Shepherd, MD, Tanya Skamene, MD, Chad Winch, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 4162.

https://doi.org/10.1182/blood.V128.22.4162.4162

Published: 2016

Journal Articles

Combined Modality Therapy in the Upfront Treatment of Patients with Primary Central Nervous System Lymphoma: A Systematic Review

Andrew Aw, MD FRCPC, Lee Mozessohn, MD FRCPC, Isabelle Bence-Bruckler, MD FRCPC, Rena Buckstein, MD FRCPC, Matthew Cheung, MD SM, FRCPC

Blood (2015) 126 (23): 5606.

https://doi.org/10.1182/blood.V126.23.5606.5606

Published: 2015

Journal Articles

Combined Modality Therapy Versus Chemotherapy Alone As an Induction Regimen for Primary CNS Lymphoma: A Cost-Effectiveness Analysis

Anca Prica, MD, Kelvin KW Chan, MD, MSc, FRCPC, Matthew Cheung, MD, MS, FRCP

Blood (2012) 120 (21): 969.

https://doi.org/10.1182/blood.V120.21.969.969

Published: 2012

Journal Articles

The Independent Effects of Frailty and Comorbidity On the Quality of Life in MDS Patients

Rena Buckstein, MD, Shabbir M.H. Alibhai, MD, Dina Khalaf, MD, Adam Lam, Alex Mamedov, Lisa Chodirker, MD, Liying Zhang, PhD, Martha Lenis, Matthew Cheung, MD, Jeannie Callum, MD, Janey Hsiao, MD, Yulia Lin, MD, Kenneth Rockwood, MD, Richard A. Wells, MD, DPhil

Blood (2012) 120 (21): 699.

https://doi.org/10.1182/blood.V120.21.699.699

Published: 2012

Journal Articles

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

Neil L Berinstein, MD, FRCPC, Nancy M Pennell, B Sc, Mary-Anne Cussen, RN, BScN, CCRP, Kevin R Imrie, MD, Eugenia Piliotis, MD, FRCPC, Rena Buckstein, MD, Zeina Ghorab, MD, Ellen Anne Miles, MSc, Alden E. Chesney, MD, Matthew Cheung, MD

Blood (2012) 120 (21): 3681.

https://doi.org/10.1182/blood.V120.21.3681.3681

Published: 2012

Journal Articles

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Nancy M Pennell, B Sc, Matthew Cheung, MD, MS, FRCP, Lisa K Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Kevin R Imrie, MD, Rena Buckstein, MD, FRCPC, Cindy Davidson, RN, Mary-Anne Cussen, RN, BScN, CCRP, Zeina Ghorab, MD, Alden Chesney, MD, FRCPC, Neil L Berinstein, MD, FRCPC

Blood (2011) 118 (21): 2701.

https://doi.org/10.1182/blood.V118.21.2701.2701

Published: 2011

Journal Articles

Deriving Health Utility Values From a Health-Related Quality of Life Instrument in Non-Hodgkin Lymphoma Patients

Nina Lathia, MSc, Pierre K Isogai, B.Sc, Jeffrey S Hoch, PhD, Carlo De Angelis, PharmD, Matthew Cheung, MD, FRCPC, Scott Walker, MScPhm, Nicole Mittmann, PhD

Blood (2011) 118 (21): 2065.

https://doi.org/10.1182/blood.V118.21.2065.2065

Published: 2011

Journal Articles

Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL)

Nicole Mittmann, PhD, Matthew Cheung, MD, FRCPC, Pierre K Isogai, B.Sc, Refik Saskin, Ning Liu, Jeffrey S Hoch, Natasha Leighl, BSc, MD, MSc, Maureen E Trudeau, William K Evans, Katie N Dainty, Craig C. Earle, MD, MSc

Blood (2011) 118 (21): 2068.

https://doi.org/10.1182/blood.V118.21.2068.2068

Published: 2011

Journal Articles

Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis

Lee Mozessohn, MD, Matthew Cheung, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC, Neil L Berinstein, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, John Kuruvilla, MD, FRCPC, Eugenia Piliotis, MD, FRCPC, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4981.

https://doi.org/10.1182/blood.V118.21.4981.4981

Published: 2011

Journal Articles

Combined Modality Therapy Versus Chemotherapy Alone as An Induction Regimen for Primary CNS Lymphoma: a Decision Analysis.

Anca Prica, MD, Kelvin K Chan, MD, Lisa Hicks, MD, MSc, Matthew Cheung, MD

Blood (2010) 116 (21): 1504.

https://doi.org/10.1182/blood.V116.21.1504.1504

Published: 2010

Journal Articles

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Sita Bhella, MD, Neil L Berinstein, MD, FRCPC, Nancy Pennell, BSc, Matthew Cheung, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, Violet Miliken, Marciano D. Reis, MD, FRCPC, Alden Chesney, MD, FRCPC, David Good, MD, FRCPC, Lisa Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC

Blood (2010) 116 (21): 1357.

https://doi.org/10.1182/blood.V116.21.1357.1357

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada

Diagnosis to Treatment Interval in DLBCL Is Predictive of Overall Survival in a Large, Population-Based Registry

Appropriateness of B12 Administration in a Real-World Population

Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

Examining Convergent Construct Validity and Inter-Rater Reliability Between ESMO-MCBS and ASCO-VF When Evaluating Hematologic Malignancies

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent

Days Spent at Home in the Last 6 Months of Life. a Potential Patient-Determined Quality Indicator for Patients with Hematologic Malignancies at the End of Life

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Combined Modality Therapy in the Upfront Treatment of Patients with Primary Central Nervous System Lymphoma: A Systematic Review

Combined Modality Therapy Versus Chemotherapy Alone As an Induction Regimen for Primary CNS Lymphoma: A Cost-Effectiveness Analysis

The Independent Effects of Frailty and Comorbidity On the Quality of Life in MDS Patients

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Deriving Health Utility Values From a Health-Related Quality of Life Instrument in Non-Hodgkin Lymphoma Patients

Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL)

Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis

Combined Modality Therapy Versus Chemotherapy Alone as An Induction Regimen for Primary CNS Lymphoma: a Decision Analysis.

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only